coteauBeta Get App

WAT

Waters Corporation
$442.83
+1.97% Oct 20 close
Health CareS&P 500 Compare
1M3M6M1Y2Y
-17%-6%+6%+18%+29%Oct 2025Oct 2026Apr 2026
WATSPY
1W
+3.2%
1M
+5.0%
3M
+20.5%
6M
+32.1%
YTD
+16.6%
1Y
+29.0%

Live chart

Loading live chart…

What they do

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products.

Healthcare · Diagnostics & Research

For information only · Important disclosures

Grades vs sector

Momentum
60th percentile in sector
B-
12-1 return: +25.7%
Percentile within its GICS sector across the S&P 1500.
Growth
98th percentile in sector
A+
Revenue growth (YoY): +113.4%
Percentile within its GICS sector across the S&P 1500.
Value
17th percentile in sector
D
Forward E/P: 3.8% · EBITDA/EV: 3.0%
Percentile within its GICS sector across the S&P 1500.
Profitability
32nd percentile in sector
D+
Profit margin: +3.6% · Return on equity: +1.9%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 104 of 499 · 12-month momentum 38.3%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
Idexx Laboratories Now #251 Largest Company, Surpassing Waters
Nasdaq · Oct 20

Key stats

Market value$44.9B
P/E (last 12 months)115.8
P/E (next 12 months, estimated)27.7
52-week range$282.77 – $459.62
Revenue growth (latest quarter vs a year ago)+113.4%
Dividend yieldNo dividend
Analyst consensusBuy (23)
Average analyst price target$464.30 (+5%)
Valuation and fundamentals

Valuation & fundamentals

No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).

Earnings

Next report: 2026-11-03 · before open · EPS est 4.00
24-1125-0225-0525-0825-1126-0226-0526-080.004.53
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-043.013.05+1.4%
2026-05-052.312.70+17.0%
2026-02-094.514.53+0.5%
2025-11-043.223.40+5.5%
2025-08-042.942.95+0.3%
2025-05-062.222.25+1.2%
2025-02-124.034.10+1.7%
2024-11-012.682.93+9.4%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.6B+113.4%
2026-03-31$1.3B–
2025-12-31$932.4M–
2025-09-30$799.9M–
2025-06-30$771.0M–
Analyst actions
TD Cowen
2026-10-13 · main
Buy → Buy
PT $515
Barclays
2026-10-07 · main
Overweight → Overweight
PT $500
Guggenheim
2026-10-01 · main
Buy → Buy
PT $490
Goldman Sachs
2026-09-21 · main
Buy → Buy
PT $515
UBS
2026-09-09 · up
Neutral → Buy
PT $490
Piper Sandler
2026-08-27 · up
Neutral → Overweight
PT $480
Insider trades
Kuebler Christopher A
Director · 2026-08-06
Sell
$1.4M
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 17:57:59 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

How it worksDisclaimerTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026